prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 | 29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39|40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |review
The primary mechanism by which HDL and apoA-I and apoA-I mimetic peptides exert their beneficial effect has been presumed to be the enhancement of reverse cholesterol transport. However, apoA-I has also been shown to be capable of removing "seeding molecules" from LDL, thus preventing the oxidation of LDL-derived phospholipids to those that are thought to be responsible for the inflammatory response characteristic of atherosclerosis.

The LDL treated with apoA-I was unable to generate lipid hydroperoxides, nor was it able to induce monocyte adherence or monocyte chemotactic activity when added to human artery wall cocultures.